BMAC Enhanced Coronary Artery Bypass Grafting (CABG)
This study is currently recruiting participants.
Verified March 2012 by Harvest Technologies
Sponsor:
Harvest Technologies
Information provided by (Responsible Party):
Harvest Technologies
ClinicalTrials.gov Identifier:
NCT01061580
First received: December 16, 2009
Last updated: March 16, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Injection of concentrated bone marrow cells into the myocardium during CABG procedure.
| Condition | Intervention | Phase |
|---|---|---|
|
Congestive Heart Failure |
Device: Harvest SmartPReP2 BMAC System |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Dose Response Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting (CABG) Surgery |
Resource links provided by NLM:
Further study details as provided by Harvest Technologies:
Primary Outcome Measures:
- Changes in left ventricular function [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- QOL (Rand 36; Minnesota Living with Heart Failure Questionnaire) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- NYHA or CCS classification evaluation [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- Changes in left ventricular ejection fraction [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- Changes in left ventricular end-diastolic volume [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- Safety [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 20 |
| Study Start Date: | May 2010 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: CABG plus BMAC Injection
Injection of Bone Marrow Aspirate Concentrate (BMAC) into ischemic myocardium following CABG during the same open procedure
|
Device: Harvest SmartPReP2 BMAC System
Injection of 10, 15, or 20 cc of BMAC
|
Detailed Description:
Injection of autologous concentrated bone marrow cells into the myocardium during CABG procedure.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be enrolled in the trial:
- Age 18 years and ability to understand the planned treatment.
- Patients with ischemic congestive heart failure requiring by pass surgery
- Congestive heart failure with ejection fraction 40%.
- Serum bilirubin, SGOT and SGPT 2.5 time the upper level of normal.
- Serum creatinine < 3.0 or no dialysis.
- NYHA performance status > 3.
- Negative pregnancy test (in women with childbearing potential).
- Subject has read and signed the IRB approved Informed Consent form
- Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Creatinine ≤ 3.0 mg / Dl, and/or no dialysis, INR ≤ 1.6 unless on Coumadin, or PTT <1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR<1.6 at the time of randomization/surgery
Exclusion Criteria:
Subjects will be excluded if they meet any of the exclusion criteria:
- Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study.
- History of Prior Radiation Exposure for oncological treatment.
- History of Bone Marrow Disorder (especially NHL, MDS) that prohibit transplantation.
- History of abnormal Bleeding or Clotting.
- History of Liver Cirrhosis.
- Acute Myocardial Infarction < 4 weeks from treatment date.
- Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemocult unless follow-up studies reveal patient to be cancer free.
- Active clinical infection being treated by antibiotics within one week of enrollment
- Terminal renal failure with existing dependence on dialysis
- Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent.
- Unable to have 250cc bone marrow harvested.
- Medical risk that precludes anesthesia or ASA Class 5
- History of ventricular arrhythmia if AICD is not present.
- History of ventricular aneurysm.
- Concurrent surgery such as CABG with valve surgery.
- Minimally Invasive bypass surgery
- Life expectancy <6 months due to concomitant illnesses
- Treatment with immunosuppressant drugs (including Prednisone > 5 mg per day)
- Patients undergoing urgent by pass surgical procedure
- Patients with HGB A1C > 8.5%
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01061580
Contacts
| Contact: Jack Bonasera | 508-732-7530 | jbonasera@harvesttech.com |
| Contact: Jeff Lindquist | 508-732-7519 | jlindquist@harvesttech.com |
Locations
| India | |
| Medanta The Medicity | Recruiting |
| Gurgaon, Haryana, India, 122 001 | |
| Contact: Naresh Trehan, MD +91- 124 4141414 info@medanta.org | |
| Principal Investigator: Naresh Trehan, MD | |
Sponsors and Collaborators
Harvest Technologies
Investigators
| Principal Investigator: | Naresh Trehan, MD | Medanta-The Medicity |
More Information
No publications provided
| Responsible Party: | Harvest Technologies |
| ClinicalTrials.gov Identifier: | NCT01061580 History of Changes |
| Other Study ID Numbers: | 2009-1 |
| Study First Received: | December 16, 2009 |
| Last Updated: | March 16, 2012 |
| Health Authority: | India: Drugs Controller General of India |
Keywords provided by Harvest Technologies:
|
Bone Marrow Concentrate CABG Cardiac Stem Cell |
Additional relevant MeSH terms:
|
Heart Failure Heart Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 22, 2013